Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | NEK1 | Q96PY6 | 3/20 | 0.35 |
| ▸ | DAO | P14920 | 4/20 | 0.35 |
| ▸ | DDO | Q99489 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3776982 | 0.90 | KDM4E (0.39) | NEK1P2RX7KCNH2KDM4E | |
| SCHEMBL3779905 | 0.89 | KDM4E (0.38) | NEK1DAODDOHTR1ACYP1A2 | |
| SCHEMBL3778310 | 0.84 | ALDH1A1 (0.39) | PTGS1PTGS2DAODDO | |
| SCHEMBL3785180 | 0.84 | KDM4E (0.47) | PTGS1NEK1KCNH2KDM4E | |
| SCHEMBL3784913 | 0.79 | PTGS2 (0.41) | PTGS1PTGS2NEK1KDM4E | |
| SCHEMBL3344884 | 0.78 | SLC2A1 (0.39) | PTGS1PTGS2DAO | |
| SCHEMBL3345036 | 0.74 | PTGS2 (0.41) | PTGS1PTGS2DAO | |
| SCHEMBL3778300 | 0.74 | PSIP1 (0.34) | PTGS1PTGS2NEK1DAODDO | |
| SCHEMBL3781883 | 0.71 | ALDH1A1 (0.40) | P2RX7KCNH2KDM4E | |
| SCHEMBL3776006 | 0.70 | PTGDR (0.39) | PTGS1CYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928457-B1 | QUINOLINES AND THEIR THERAPEUTIC USE | PULMAGEN THERAPEUTICS ASTHMA LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| US-7858640-B2 | Quinolines and their therapeutic use | PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | GB005, INC. | 2009-06-18 | — | — | US | disclosed |
| EP-1928457-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | Argenta Discovery Limited (GB) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007036743-A2 | QUINOLINES AND THEIR THERAPEUTIC USE | ARGENTA DISCOVERY LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156600-A1 | Quinolines and Their Therapeutic Use | NR3C1, NR3C2, NR1H3 | PTGS1 584/4885PTGS2 821/4885NEK1 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.